OPKO Health Inc.
An integrated healthcare company in pharmaceuticals and diagnostic laboratory services.
OPK | TA
Overview
Corporate Details
- ISIN(s):
- US68375N1037
- LEI:
- Country:
- Israel
- Address:
- 4400 Biscayne Blvd., 33137 Miami
- Website:
- https://www.opko.com
- Industry:
- Other human health activities
Description
OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-30 00:23 |
Immediate Report
|
English | 36.5 KB | ||
| 2025-10-29 15:17 |
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regene…
|
English | 289.1 KB | ||
| 2025-10-29 15:17 |
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regene…
|
English | 36.5 KB | ||
| 2025-10-28 15:09 |
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treat…
|
English | 302.7 KB | ||
| 2025-10-28 15:09 |
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treat…
|
English | 36.4 KB | ||
| 2025-10-23 11:02 |
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
|
English | 179.7 KB | ||
| 2025-10-23 11:02 |
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
|
English | 36.4 KB | ||
| 2025-10-02 23:09 |
Immediate Report
|
English | 514.3 KB | ||
| 2025-10-02 23:09 |
Immediate Report
|
English | 36.3 KB | ||
| 2025-09-16 11:31 |
Labcorp completes acquisition of select assets of BioReference.
|
English | 117.0 KB | ||
| 2025-09-16 11:31 |
Labcorp completes acquisition of select assets of BioReference.
|
English | 36.4 KB | ||
| 2025-08-20 01:46 |
Immediate Report
|
English | 51.4 KB | ||
| 2025-08-20 01:46 |
Immediate Report
|
English | 36.3 KB | ||
| 2025-08-10 02:28 |
Immediate Report
|
English | 51.5 KB | ||
| 2025-08-10 02:28 |
Immediate Report
|
English | 36.3 KB |
Automate Your Workflow. Get a real-time feed of all OPKO Health Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OPKO Health Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OPKO Health Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
